1. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.
- Author
-
Liu, Shi, Deng, Rui, Zhou, Bin, Liang, Xieer, Liu, Zhihong, Peng, Jie, Chen, Jinjun, Zhou, Yuanping, Guo, Yabing, Chen, Yongpeng, Li, Wanying, Shen, Sheng, Lu, Xingyu, Zhao, Siru, Liao, Xingmei, Liang, Hongyan, Lan, Yu, Hou, Jinlin, Fan, Rong, and Sun, Jian
- Subjects
- *
LIVER tumors , *DNA , *NUCLEOSIDES , *HEPATITIS viruses , *RNA , *ANTIVIRAL agents , *RESEARCH funding , *CHRONIC hepatitis B , *HEPATOCELLULAR carcinoma , *LONGITUDINAL method , *PHARMACODYNAMICS , *DISEASE complications - Abstract
Background: Whether serum hepatitis B virus (HBV) RNA associates with hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients has not been fully elucidated.Methods: We enrolled 2974 patients receiving nucleos(t)ide analogues (NAs) from a prospective, observational CHB cohort to investigate the effect of serum HBV RNA, measured at study entry (baseline), on HCC development, using Cox regression analyses.Results: During median follow-up of 4.4 years, 90 patients developed HCC. Patients with detectable baseline HBV RNA (n = 2072) exhibited significantly higher HCC risk than those with undetectable level (5-year HCC incidence estimated by Kaplan-Meier method: 4.1% versus 1.8%, P = .009; adjusted hazard ratio [aHR] = 2.21, P = .005). HBV RNA levels of 609-99 999 and ≥100 000 copies/mL were associated with incrementally increasing HCC risk (aHR = 2.15 and 3.05, respectively; P for trend = .003), compared to undetectable level (<609 copies/mL). Moreover, patients with single-detectable either HBV DNA or RNA and double-detectable DNA and RNA had 1.57- and 4.02-fold higher HCC risk, respectively, than those with double-undetectable DNA and RNA (P for trend = .001).Conclusions: High-level HBV RNA is associated with increased HCC risk in NAs-treated patients. Achieving undetectable HBV RNA may contribute to better clinical outcomes, indicating it could be a valuable endpoint of anti-HBV treatment. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF